Guardian Pharmacy Services (GRDN) to Release Earnings on Thursday

Guardian Pharmacy Services (NYSE:GRDN) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Guardian Pharmacy Services to announce earnings of $0.2617 per share and revenue of $340.4490 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last announced its earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The business had revenue of $336.60 million for the quarter, compared to analyst estimates of $329.89 million. During the same quarter last year, the business earned $0.22 earnings per share. The company’s revenue for the quarter was up 2.2% compared to the same quarter last year. On average, analysts expect Guardian Pharmacy Services to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Guardian Pharmacy Services Stock Down 0.5%

Guardian Pharmacy Services stock opened at $40.62 on Wednesday. The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of 48.95, a PEG ratio of 2.68 and a beta of 0.10. The company has a fifty day simple moving average of $40.80 and a 200-day simple moving average of $36.88. Guardian Pharmacy Services has a 52-week low of $19.30 and a 52-week high of $44.00.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of institutional investors have recently added to or reduced their stakes in GRDN. Occudo Quantitative Strategies LP boosted its position in shares of Guardian Pharmacy Services by 94.8% in the fourth quarter. Occudo Quantitative Strategies LP now owns 31,266 shares of the company’s stock worth $941,000 after buying an additional 15,218 shares during the period. California State Teachers Retirement System increased its stake in Guardian Pharmacy Services by 3,376.7% during the second quarter. California State Teachers Retirement System now owns 22,842 shares of the company’s stock valued at $487,000 after purchasing an additional 22,185 shares during the last quarter. Oxford Asset Management LLP bought a new position in Guardian Pharmacy Services in the fourth quarter worth about $330,000. New York State Common Retirement Fund boosted its position in Guardian Pharmacy Services by 113.5% during the 4th quarter. New York State Common Retirement Fund now owns 7,900 shares of the company’s stock valued at $238,000 after purchasing an additional 4,200 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Guardian Pharmacy Services by 30.1% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,082 shares of the company’s stock valued at $238,000 after purchasing an additional 2,101 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Zacks Research downgraded shares of Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Truist Financial increased their target price on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Bank of America increased their target price on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Wall Street Zen downgraded Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Oppenheimer upped their price objective on Guardian Pharmacy Services from $38.00 to $43.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.